ContractRepurchase Agreement • March 23rd, 2017 • Northwest Biotherapeutics Inc • Pharmaceutical preparations
REPURCHASE AGREEMENT (this “Agreement”), dated as of March 8, 2017, among Northwest Biotherapeutics, a Delaware corporation (the “Company”) and each of the undersigned beneficial owners (each, a “Holder”, and, collectively, the “Holders”) of one-hundred percent of the Company’s 5.00% Convertible Senior Notes Due 2017 (the “Notes”), issued pursuant to that certain Indenture dated as of August 19, 2014 between The Bank of New York Mellon (the “Trustee”) and the Company (the “Indenture”).
FIRST SUPPLEMENTAL INDENTUREFirst Supplemental Indenture • March 23rd, 2017 • Northwest Biotherapeutics Inc • Pharmaceutical preparations • New York
THIS FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”), dated and effective as of March 17, 2017, between Northwest Biotherapeutics, Inc. (the “Company”) and The Bank of New York Mellon, a New York banking corporation, as trustee (the “Trustee”). Capitalized terms used herein and not otherwise defined have the meaning ascribed to such terms in the Indenture (as defined below).
